MT-CYB and leishmaniasis: Comprehensive MoA studies confirmed that DNDI-6174 employs a different mechanism of action compared to anti-leishmanials in clinical use as well as the other NCEs in the current global leishmaniasis portfolio, an important consideration if one envisages to combining drugs for a better therapeutic outcome This pyrrolopyrimidine inhibits Leishmania cytochrome b, a component of complex III (cytochrome bc1) of the parasite’s electron transport chain.